ABBV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AbbVie Inc. (ABBV) is currently not a strong buy for a beginner investor with a long-term strategy. While the company demonstrates strong dividend growth and revenue increases, the recent financial performance shows a significant decline in net income and EPS, raising concerns about profitability. Additionally, the lack of strong trading signals, neutral sentiment from hedge funds and insiders, and recent congressional sales suggest caution. Analysts remain positive on the stock's long-term potential, but the mixed sentiment and technical indicators suggest waiting for a better entry point.
The MACD is positive but contracting, RSI is neutral at 55.459, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 223.408, and resistance is at 235.621. The stock is trading near its pivot point of 229.514, indicating no strong momentum in either direction.
AbbVie achieved over $1 billion in annual sales for 10 therapies in
Dividend yield of 2.9% with a 5.5% increase in 2025 and over 330% growth since IPO.
Positive results from the AFFIRM study for Crohn's disease treatment.
Analysts from RBC, Barclays, and Piper Sandler maintain positive ratings with price targets ranging from $260 to $299.
Significant decline in net income (-5743.75% YoY) and EPS (-5200.00% YoY) in Q4
Concerns about AbbVie's long-term growth post-2028 due to competition and market saturation.
Congressional trading data shows 4 sale transactions and no purchases, indicating cautious sentiment.
Wolfe Research downgraded the stock to Peer Perform, citing limited visibility on future growth.
In Q4 2025, revenue increased by 10.04% YoY to $16.62 billion, and gross margin improved to 72.61%. However, net income dropped significantly to $1.81 billion (-5743.75% YoY), and EPS fell to $1.02 (-5200.00% YoY), reflecting increased R&D and acquisition expenses.
Analysts are generally positive, with RBC, Barclays, and Piper Sandler maintaining Outperform or Overweight ratings and price targets ranging from $260 to $299. However, UBS and Citi have Neutral ratings with lower price targets, and Wolfe Research downgraded the stock to Peer Perform.
